Smithbridge Asset Management Inc. DE Cuts Stake in AbbVie Inc. $ABBV

Smithbridge Asset Management Inc. DE lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 7.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 29,215 shares of the company’s stock after selling 2,369 shares during the quarter. AbbVie comprises approximately 1.0% of Smithbridge Asset Management Inc. DE’s investment portfolio, making the stock its 26th largest holding. Smithbridge Asset Management Inc. DE’s holdings in AbbVie were worth $7,352,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC grew its position in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. raised its holdings in AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares in the last quarter. Ieq Capital LLC lifted its stake in AbbVie by 4.6% in the second quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after acquiring an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC grew its holdings in AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after acquiring an additional 612,702 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ABBV. Cantor Fitzgerald increased their price objective on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 target price for the company in a research note on Thursday. Wells Fargo & Company increased their target price on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, July 10th. Finally, Barclays raised their price target on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $275.50.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong post-Humira growth: AbbVie reported first-quarter 2026 revenue of $15.002 billion, up 12.4% year over year on a reported basis and 10.3% operationally. Adjusted diluted EPS of $2.65 exceeded internal expectations despite a $0.41-per-share headwind from acquired in-process research and development costs, supporting confidence in the company’s ability to replace Humira-related sales. Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?
• Positive Sentiment: Analyst support strengthened: Wolfe Research upgraded AbbVie, citing the company’s pipeline strength and valuation. BNP Paribas Exane also indicated that the stock could rise, adding to the bullish research tone. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation AbbVie Stock Price Expected to Rise, BNP Paribas Exane Analyst Says
• Positive Sentiment: Commercial and pipeline catalysts: AbbVie’s Botox filing and Canada’s reimbursement recommendation for UBRELVY in adult migraine treatment could expand revenue opportunities in aesthetics and neuroscience. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Neutral Sentiment: Updates on venetoclax in high-risk myelodysplastic syndromes and a completed Phase 3 Botox jawline study provide potential longer-term catalysts, but their financial impact depends on additional data, regulatory decisions, and commercialization. AbbVie’s Venetoclax Combo in High-Risk MDS
• Negative Sentiment: Erste Group Bank lowered its AbbVie earnings estimates, highlighting a counterpoint to the positive upgrades and potentially limiting near-term upside. Erste Group Bank Lowers Earnings Estimates for AbbVie

AbbVie Trading Up 1.0%

ABBV stock opened at $251.20 on Friday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The company has a market capitalization of $443.82 billion, a P/E ratio of 70.96, a PEG ratio of 0.82 and a beta of 0.30. The business has a 50 day simple moving average of $244.51 and a 200-day simple moving average of $225.96.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the prior year, the company earned $2.97 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts predict that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.